WO2004058353A3 - Therapeutic use of selective noradrenaline reuptake inhibitors - Google Patents
Therapeutic use of selective noradrenaline reuptake inhibitors Download PDFInfo
- Publication number
- WO2004058353A3 WO2004058353A3 PCT/GB2003/005693 GB0305693W WO2004058353A3 WO 2004058353 A3 WO2004058353 A3 WO 2004058353A3 GB 0305693 W GB0305693 W GB 0305693W WO 2004058353 A3 WO2004058353 A3 WO 2004058353A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reuptake inhibitors
- noradrenaline reuptake
- therapeutic use
- selective noradrenaline
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003290363A AU2003290363A1 (en) | 2002-12-24 | 2003-12-23 | Therapeutic use of selective noradrenaline reuptake inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0230135A GB0230135D0 (en) | 2002-12-24 | 2002-12-24 | Compounds and their uses |
GB0230135.6 | 2002-12-24 | ||
GB0316203.9 | 2003-07-10 | ||
GB0316203A GB0316203D0 (en) | 2003-07-10 | 2003-07-10 | Compounds and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004058353A2 WO2004058353A2 (en) | 2004-07-15 |
WO2004058353A3 true WO2004058353A3 (en) | 2004-09-23 |
Family
ID=32683993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/005693 WO2004058353A2 (en) | 2002-12-24 | 2003-12-23 | Therapeutic use of selective noradrenaline reuptake inhibitors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003290363A1 (en) |
WO (1) | WO2004058353A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
MXPA05007379A (en) | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof. |
EP1745029A1 (en) | 2004-04-30 | 2007-01-24 | Warner-Lambert Company LLC | Substituted morpholine compounds for the treatment of central nervous system disorders |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE614616A (en) * | 1961-03-03 | 1962-09-03 | Geigy Ag J R | Process for the preparation of dibenzoazepine compounds |
EP0319061A1 (en) * | 1987-11-28 | 1989-06-07 | Akzo N.V. | Medicament with antiemetic action |
WO1998050044A1 (en) * | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
WO1999016769A1 (en) * | 1997-09-26 | 1999-04-08 | Monash University | Resolution of optically-active compounds |
US6034091A (en) * | 1993-03-02 | 2000-03-07 | John S. Nagle | Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures |
WO2001062236A2 (en) * | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
WO2002043652A2 (en) * | 2000-11-29 | 2002-06-06 | Ramot At Tel-Aviv University Ltd. | Anti-proliferative drugs |
WO2002053140A2 (en) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
WO2002076461A1 (en) * | 2001-03-26 | 2002-10-03 | Serdar Murat Dursun | Combination of reboxetine and citalopram |
-
2003
- 2003-12-23 WO PCT/GB2003/005693 patent/WO2004058353A2/en not_active Application Discontinuation
- 2003-12-23 AU AU2003290363A patent/AU2003290363A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE614616A (en) * | 1961-03-03 | 1962-09-03 | Geigy Ag J R | Process for the preparation of dibenzoazepine compounds |
EP0319061A1 (en) * | 1987-11-28 | 1989-06-07 | Akzo N.V. | Medicament with antiemetic action |
US6034091A (en) * | 1993-03-02 | 2000-03-07 | John S. Nagle | Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures |
WO1998050044A1 (en) * | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
WO1999016769A1 (en) * | 1997-09-26 | 1999-04-08 | Monash University | Resolution of optically-active compounds |
WO2001062236A2 (en) * | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
WO2002043652A2 (en) * | 2000-11-29 | 2002-06-06 | Ramot At Tel-Aviv University Ltd. | Anti-proliferative drugs |
WO2002053140A2 (en) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
WO2002076461A1 (en) * | 2001-03-26 | 2002-10-03 | Serdar Murat Dursun | Combination of reboxetine and citalopram |
Non-Patent Citations (15)
Title |
---|
BLACKBURN T P ET AL: "Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo", EUROPEAN JOURNAL OF PHARMACOLOGY 1978 NETHERLANDS, vol. 52, no. 3-4, 1978, pages 367 - 374, XP001197258 * |
BOLDEN-WATSON C ET AL: "Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes.", LIFE SCIENCES. 1993, vol. 52, no. 12, 1993, pages 1023 - 1029, XP001197330, ISSN: 0024-3205 * |
FRAZER A: "Norepinephrine involvement in antidepressant action", 2000, JOURNAL OF CLINICAL PSYCHIATRY 2000 UNITED STATES, VOL. 61, NR. SUPPL. 10, PAGE(S) 25-30, ISSN: 0160-6689, XP008032989 * |
FREDRIKSON M ET AL: "Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline.", BRITISH JOURNAL OF CANCER. OCT 1994, vol. 70, no. 4, October 1994 (1994-10-01), pages 642 - 645, XP008032984, ISSN: 0007-0920 * |
GUPTA Y K ET AL: "Involvement of 5-HT1A and 5-HT2 receptor in cisplatin induced emesis in dogs.", INDIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, (2002 OCT) 46 (4) 463-7. JOURNAL CODE: 0374707. ISSN: 0019-5499., October 2002 (2002-10-01), XP008032799 * |
HOLLAND J C ET AL: "A CONTROLLED TRIAL OF FLUOXETINE AND DESIPRAMINE IN DEPRESSED WOMED WITH ADVANCED CANCER", PSYCHO-ONCOLOGY, WILEY, CHICHESTER, GB, vol. 7, no. 4, July 1998 (1998-07-01), pages 291 - 300, XP008028709, ISSN: 1057-9249 * |
KILOH L.G. ET AL: "A double blind comparative trial of viloxazine and amitriptyline in patients suffering from endogenous depression.", AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 13/4 (357-360). CODEN: ANZPBQ, 1979, XP008032797 * |
KIMMEL H L ET AL: "Opioid receptor agonists and antagonists alter GBR12909-induced turning in the rat", EUROPEAN JOURNAL OF PHARMACOLOGY 19 FEB 1998 NETHERLANDS, vol. 343, no. 2-3, 19 February 1998 (1998-02-19), pages 119 - 127, XP001197319, ISSN: 0014-2999 * |
PAWLOWSKI L ET AL: "EFFECTS OF ANTIDEPRESSANT DRUGS, SELECTIVE NORADRENALINE- OR 5-HYDROXYTRYPTAMINE UPTAKE INHIBITORS, ON APOMORPHINE-INDUCED HYPOTHERMIA IN MICE", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 88, no. 2, 1986, pages 240 - 246, XP009027103, ISSN: 0033-3158 * |
PRAKASH C ET AL: "CYCLIC VOMITING SYNDROME IN ADULTS: CLINICAL FEATURES AND RESPONSE TO TRICYCLIC ANTIDEPRESSANTS", AMERICAN JOURNAL OF GASTROENTEROLOGY, NEW YORK, NY, US, vol. 94, no. 10, 1999, pages 2855 - 2860, XP001189009, ISSN: 0002-9270 * |
PRAKASH C ET AL: "TRICYCLIC ANTIDEPRESSANTS FOR FUNCTIONAL NAUSEA AND VOMITING CLINICAL OUTCOME IN 37 PATIENTS", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 9, September 1998 (1998-09-01), pages 1951 - 1956, XP008028464, ISSN: 0163-2116 * |
PRELUSKY, DAN B. ET AL: "The efficacy of various classes of anti- emetics in preventing deoxynivalenol-induced vomiting in swine", NATURAL TOXINS , 1(5), 296-302 CODEN: NATOEE; ISSN: 1056-9014, 1993, XP008032795 * |
PYTHON A ET AL: "Effects of nisoxetine, a selective noradrenaline transporter blocker, on sleep in rats", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR 1997 UNITED STATES, vol. 58, no. 2, 1997, pages 369 - 372, XP001197322, ISSN: 0091-3057 * |
ROSS S B ET AL: "Tricyclic antidepressant agents. II. Effect of oral administration on the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices of the midbrain-hypothalamus region of the rat.", ACTA PHARMACOLOGICA ET TOXICOLOGICA. 1975, vol. 36, no. 5, 1975, pages 395 - 408, XP008033046, ISSN: 0001-6683 * |
SAWHNEY M S ET AL: "TRICYCLIC ANTIDEPRESSANTS FOR PERSISTENT OR RECURRENT VOMITING IN DIABETIC PATIENTS", GASTROENTEROLOGY, W.B.SAUNDERS COMPANY, PHILADELPHIA, US, vol. 120, no. 5, SUPPL 1, 20 May 2001 (2001-05-20), pages A243, XP008028462, ISSN: 0016-5085 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004058353A2 (en) | 2004-07-15 |
AU2003290363A1 (en) | 2004-07-22 |
AU2003290363A8 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008051197A3 (en) | Small-molecule botulinum toxin inhibitors | |
EG25011A (en) | Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments. | |
WO2004037176A3 (en) | Quinazolinones and derivatives thereof as factor xa inhibitors | |
WO2007076423A3 (en) | INHIBITORS OF Akt ACTIVITY | |
WO2007014930A3 (en) | Polyammonium/polysiloxane copolymers | |
WO2008054676A3 (en) | Medical devices and methods of using the same | |
WO2007019439A3 (en) | Block copolymer compositions and uses thereof | |
ZA200502247B (en) | Selected CGRP antagonists, method for production and use thereof as medicament. | |
WO2007011741A3 (en) | Stable organic devices | |
WO2003082208A8 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
MX2007002470A (en) | Substituted phenylaminothiazoles and use thereof. | |
MX256798B (en) | Dispersions of polymers in organic medium, and compositions comprising them. | |
AP2005003467A0 (en) | N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors. | |
WO2005118831A3 (en) | Polymeric compositions and related methods of use | |
DK1670458T3 (en) | 1-Amino-2-oxy-substituted tetrahydronaphthalane derivatives, processes for their preparation and their use as antiphlogistics | |
IL180551A0 (en) | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting | |
WO2006118884A3 (en) | Drug delivery devices and related components, systems and methods | |
WO2006034035A3 (en) | Treatment of ischemia | |
AU2002228317A1 (en) | Benz-1,3-azole derivatives and their uses as heparanase inhibitors | |
WO2004103283A3 (en) | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | |
NO20052557L (en) | Morpholine derivatives for use as dopamine agonists in the treatment of, inter alia, sexual dysfunction. | |
WO2006029398A3 (en) | All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use | |
WO2006050826A3 (en) | Treatment of mastitis with enrofloxacin | |
WO2005032490A3 (en) | Cyclic diamines and derivatives as factor xa inhibitors | |
NO20053588D0 (en) | Acylaminothiazole derivatives, their preparation and use as beta-amyloid peptide production inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |